In an after-event review, Kevin Kalinsky, MD, remarks on how updates at ASCO 2024 focused on patients with hormone receptor–positive, HER2-negative or ultralow breast cancer. The DESTINY-Breast06 study evaluated trastuzumab deruxtecan in patients with HER2-low disease, showing improved progression-free survival compared with chemotherapy. Notably, even patients with ultralow disease benefited from trastuzumab deruxtecan.
The postMONARCH study investigated fulvestrant plus abemaciclib vs fulvestrant plus placebo as a second-line treatment, demonstrating improved progression-free survival without unexpected toxicities. This suggests a viable strategy for patients with endocrine-resistant disease, regardless of biomarker status. Overall, the findings support considering trastuzumab deruxtecan earlier for patients with low disease burden and continuing CDK4/6 inhibitor therapy with endocrine therapy switching as an option for patients with hormone receptor–positive breast cancer.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2024: Impact of New Data on Treatment Strategies for Metastatic Breast Cancer - Medscape - Jun 25, 2024.
Comments